How Wells Fargo Currently Rates Tesaro (NASDAQ:TSRO)
Wells Fargo issued “Outperform” rating on Tesaro (NASDAQ:TSRO). The firm commenced coverage coverage on shares of TSRO in a very recent research note sent to investors and clients on Friday, 4 December.
From a total of 5 analysts covering Tesaro Inc (NASDAQ:TSRO) stock, 5 rate it a ”Buy”, 0 a “Sell”, and 0 a ”Hold”. This means that 100% of the ratings are positive. Tesaro Inc was the topic of 3 analyst reports since August 24, 2015 according to the firm StockzIntelligence Inc. Zacks upgraded shares on September 1 to “Sell” rating. Leerink Swann initiated TSRO stock in a recent report from August 24 with “Outperform” rating.
Approximately 165,988 shares of stock traded hands. TESARO Inc (NASDAQ:TSRO) has declined 7.29% since May 1, 2015 and is downtrending. It has underperformed by 4.51% the S&P500.
TESARO, Inc. is oncology-focused biopharmaceutical company. The company has a market cap of $2.00 billion. The Firm acquires, in-licenses and develops oncology product candidates. It currently has negative earnings. The Firm has in-licensed and are developing three clinical-stage product candidates, rolapitant, niraparib and TSR-011.
According to Zacks Investment Research, “Tesaro, Inc. is an oncology-focused biopharmaceutical company for cancer patients. The Company’s product portfolio consists of Rolapitant, a neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting, TSR-011, an orally available anaplastic lymphoma kinase inhibitor for the treatment of non-small cell lung cancer and other cancer indications, and Niraparib, an orally active and potent poly (ADP-ribose) polymerase inhibitor for the treatment of patients with solid tumors. Tesaro, Inc. is based in Waltham, Massachusetts.” Get a free copy of the Zacks research report on TESARO Inc (TSRO).